<DOC>
	<DOCNO>NCT00028951</DOCNO>
	<brief_summary>RATIONALE : Fibrin sealant may decrease lymphedema follow surgery remove lymph node groin help seal lymphatic vessel . It yet know fibrin sealant effective decrease lymphedema follow surgery remove lymph node . PURPOSE : Randomized phase III trial determine effectiveness fibrin sealant reduce lymphedema follow surgical removal lymph node patient cancer vulva .</brief_summary>
	<brief_title>Fibrin Sealant Decreasing Lymphedema Following Surgery Remove Lymph Nodes Patients With Cancer Vulva</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence lymphedema low extremity lymph node dissection patient vulvar malignancy treat fibrin sealant v standard care . - Compare frequency surgical complication patient treat fibrin sealant v standard care . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : After radical vulvectomy hemivulvectomy lymphadenectomy , patient receive fibrin sealant surgical site . - Arm II : After surgery , patient receive standard care closure surgical site . Lymphedema assess time drain removal , week 6 , month 3 6 . Patients follow week 6 month 3 6 . PROJECTED ACCRUAL : A total 120-130 patient ( 60-65 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Postoperative Complications</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis vulvar malignancy Stage IIVB Planned radical vulvectomy hemivulvectomy AND Ipsilateral bilateral inguinal lymphadenectomy Presence groin node metastasis allow No primary secondary lymphedema low extremity PATIENT CHARACTERISTICS : Age : Over 18 Performance status : GOG 03 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 No bleeding disorder Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Albumin least 3.0 g/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No prior low extremity deep vein thrombosis Other : No known sensitivity anaphylaxis bovinederived product No know prior exposure fibrin tissue adhesive No malignancy within past 5 year except nonmelanoma skin cancer No nonhealing ulcer chronic infection lower extremity , include superficial phlebitis No prior fracture portion either leg Preoperative circumferential measurement legs must differ less 3 cm Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy prior malignancy Concurrent adjuvant chemotherapy allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy prior malignancy No prior radiotherapy pelvis , abdomen , inguinal area , low extremity Surgery : See Disease Characteristics No prior inguinal surgery No prior surgery vein artery either leg No concurrent elective surgery operative event inguinal lymphadenectomy Other : At least 30 day since prior investigational product device At least 7 day since prior anticoagulant Concurrent enrollment GOG0173 adjuvant treatment protocol allow No concurrent investigational product device</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>lymphedema</keyword>
	<keyword>perioperative/postoperative complication</keyword>
	<keyword>stage I vulvar cancer</keyword>
	<keyword>stage II vulvar cancer</keyword>
	<keyword>stage III vulvar cancer</keyword>
	<keyword>stage IVB vulvar cancer</keyword>
</DOC>